Strides gets USFDA nod to market generic cancer injection

Drug firm Strides Arcolab today said it has received approval from the US health regulator to market a generic carboplatin injection for the treatment of ovarian cancer.

Onco Therapies, a wholly-owned subsidiary of the company, has received United States Food and Drug Administration (USFDA) approval for Carboplatin injections, Strides Arcolab said in a statement.

The approval by the USFDA is for carboplatin injections in strengths of 10 mg/mL, packaged in 50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL and 600 mg/60 mL multi-dose vials, it added.

"Carboplatin is part of the oncology portfolio licensed to Pfizer in January, 2010, for the US market and is expected to be launched shortly," Strides Arcolab said.

The company said according to IMS data of June 11, the US market for generic carboplatin is worth nearly $35 million.

Carboplatin injections are indicated for the treatment of advanced ovarian cancer, it added.

Shares of Strides Arcolab were being quoted at Rs 416 apiece in afternoon trade on the BSE today, up 1.18% from their previous close.